scholarly journals Ulcerative colitis that developed during radiotherapy for prostate cancer, deteriorated rapidly and required emergency surgery

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Keiji Matsuda ◽  
Yuka Okada ◽  
Yojiro Hashiguchi ◽  
Kentaro Asako ◽  
Kohei Ohno ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Ulcerative Colitis ◽  
Emergency Surgery ◽  
Specific Antigen ◽  
Intensity Modulated Radiotherapy ◽  
Active Phase ◽  
First Case ◽  
Old Japanese ◽  
Radiation Colitis ◽  
Easy Bleeding

Abstract Background Although there are reports linking ulcerative colitis (UC) to prostate cancer (PC), those reports are of PC patients who were previously diagnosed with UC. There are no reports of the development of UC during radiotherapy. Here we describe the first case of a patient who developed UC during radiotherapy for PC. The UC progressed rapidly and required emergency surgery. Case presentation A 61-year-old Japanese man underwent a prostate biopsy at another hospital due to a high prostate-specific antigen level and was diagnosed with PC. Goserelin and bicalutamide treatment was initiated in 2019, and intensity-modulated radiotherapy (total of 60 Gy/20 Fr) was administered in 2020. Diarrhea began during the radiotherapy and bleeding began post-radiotherapy. He was admitted to another hospital 14 days after the end of the radiotherapy, and colonoscopy revealed a deep ulcer in the colon, which led to the suspicion of UC. He was transferred to our hospital, and colonoscopy showed a widespread map-like ulcer, pseudopolyposis, and very easy bleeding in the colon. We diagnosed severe UC, and it worsened rapidly with uncontrollable bleeding, which we considered an indication for surgery. Emergency surgery (a total colectomy and ileostomy creation) was performed. The specimens confirmed an extensively spreading ulcer throughout the colon. The pathological report was UC in the active phase. The postoperative course was good. Conclusions When a patient exhibits diarrhea while undergoing radiotherapy for PC, clinicians should be aware of the possibility of UC in addition to radiation colitis, and colonoscopy should be considered.

Prostate-specific Antigen Bounce After Intensity-modulated Radiotherapy for Prostate Cancer

Urology ◽  
2010 ◽  
Vol 76 (3) ◽  
pp. 728-733 ◽  
Author(s):  
Courtney Sheinbein ◽  
Bin S. Teh ◽  
Wei Y. Mai ◽  
Walter Grant ◽  
Arnold Paulino ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Intensity Modulated Radiotherapy ◽  
Intensity Modulated

scholarly journals Complete response to ethnylestradiol prolonged for almost two years in patients with castration-resistant prostate cancer

2014 ◽  
Vol 8 (11-12) ◽  
pp. 921
Author(s):  
Hiroshi Hongo ◽  
Takeo Kosaka ◽  
Mototsugu Oya
Keyword(s):  
Prostate Cancer ◽  
Needle Biopsy ◽  
Specific Antigen ◽  
Complete Response ◽  
Pathological Examination ◽  
Castration Resistant Prostate Cancer ◽  
Prostate Needle Biopsy ◽  
Combined Androgen Blockade ◽  
Castration Resistant ◽  
First Case

An 80-year-old man with an elevated prostate-specific antigen (PSA) level of 120 ng/mL) presented to the hospital in February 2011. A prostate needle biopsy was performed, and pathological examination revealed prostatic adenocarcinoma. The Gleason score was 4+5=9. Computed tomography revealed metastases of the pelvic lymph nodes. Combined androgen blockade was started. The PSA concentration decreased to 1.68 ng/mL, but started increasing again in August 2012 to 6.08 ng/mL. Although bicalutamide was discontinued due to antiandrogen withdrawal syndrome, the PSA concentration increased even more. The PSA concentration reached 21.62 ng/mL in September 2012, at which time ethnylestradiol was started. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2 years. To our knowledge, this is first case report describing a complete response to ethnylestradiol that lasted for almost 2 years in a patient with castration-resistant prostate cancer.

scholarly journals Unusual Presentation of Prostate Cancer Metastatic to the Cricoid Cartilage and Oral Cavity

2018 ◽  
Vol 2018 ◽  
pp. 1-3 ◽  
Author(s):  
Marlene Olvera ◽  
Miriam Delgado ◽  
Melchor Vázquez ◽  
José Zavala ◽  
Verónica Macedo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Oral Cavity ◽  
Metastatic Prostate Cancer ◽  
Unusual Case ◽  
Cricoid Cartilage ◽  
Specific Antigen ◽  
Regional Lymph Nodes ◽  
First Case ◽  
Metastatic Prostate Carcinoma ◽  
Laryngeal Stridor

In Mexico, prostate cancer is the second leading cause of death in men. Prostate cancer usually presents metastasis to the regional lymph nodes and bone. Hereby, we present an unusual case of metastatic prostate cancer, with affectation to the cricoid cartilage and oral cavity, being the first case to have ever been reported in Mexico. A 68-year-old Mexican man was diagnosed with prostate cancer and cribriform architecture histology with low serum level of prostate-specific antigen, debuting with laryngeal stridor. The biopsy came back positive for metastatic prostate carcinoma. During treatment with radiotherapy, metastasis developed to the oral cavity.

scholarly journals Prospective evaluation of probabilistic dose-escalated IMRT in prostate cancer

2020 ◽  
Vol 55 (1) ◽  
pp. 88-96
Author(s):  
Daniel Wegener ◽  
Bernhard Berger ◽  
Zhoulika Outtagarts ◽  
Daniel Zips ◽  
Frank Paulsen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy Oncology Group ◽  
Specific Antigen ◽  
Intensity Modulated Radiotherapy ◽  
Target Volume ◽  
Monte Carlo Algorithm ◽  
Internal Target Volume ◽  
Cancer Specific Survival ◽  
A Prospective Study

AbstractBackgroundCure- and toxicity rates after intensity-modulated radiotherapy (IMRT) of prostate cancer are dose-and volume dependent. We prospectively studied the potential for organ at risk (OAR) sparing and compensation of tumor movement with the coverage probability (CovP) concept.Patients and methodsTwenty-eight prostate cancer patients (median age 70) with localized disease (cT1c–2c, N0, M0) and intermediate risk features (prostate-specific antigen [PSA] < 20, Gleason score ≤ 7b) were treated in a prospective study with the CovP concept. Planning-CTs were performed on three subsequent days to capture form changes and movement of prostate and OARs. The clinical target volume (CTV) prostate and the OARs (bladder and rectum) were contoured in each CT. The union of CTV1–3 was encompassed by an isotropic margin of 7 mm to define the internal target volume (ITV). Dose prescription/escalation depended on coverage of all CTVs within the ITV. IMRT was given in 39 fractions to 78 Gy using the Monte-Carlo algorithm. Short-term androgen deprivation was recommended and given in 78.6% of patients.ResultsLong-term toxicity was evaluated in 26/28 patients after a median follow-up of 7.1 years. At last follow-up, late bladder toxicity (Radiation Therapy Oncology Group, RTOG) G1 was observed in 14.3% of patients and late rectal toxicities (RTOG) of G1 (7.1%) and of G2 (3.6%) were observed. No higher graded toxicity occurred. After 7.1 years, biochemical control (biochemically no evidence of disease, bNED) was 95.5%, prostate cancer-specific survival and the distant metastasis-free survival after 7.1 years were 100% each.ConclusionsCovP-based IMRT was feasible in a clinical study. Dose escalation with the CovP concept was associated by a low rate of toxicity and a high efficacy regarding local and distant control.

1267: Prostate-Specific Antigen Velocity among African-American and White Men Without Prostate Cancer

2004 ◽  
Vol 171 (4S) ◽  
pp. 334-334
Author(s):  
Walter J. Simoneaux ◽  
Caleb B. Bozeman ◽  
Brett S. Carver ◽  
Donald A. Elmajian
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
White Men
Sign in / Sign up

Export Citation Format

Share Document